Pharmaceutical - Publications - Faculty & Research - Harvard Business School

Filter Results: (1,253)

Filter Results: (1,253)

Show Results For

← Page 9 of 1,253 Results →

July 2020
Article

Lessons from the Impact of Price Regulation on the Pricing of Anticancer Drugs in Germany

By: Victoria D. Lauenroth, Aaron S. Kesselheim, Ameet Sarpatwari and Ariel Dora Stern

Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly pronounced in the U.S., it remains largely unaddressed there. In Europe, however, different approaches to regulating drug prices have been... View Details

Keywords: Pharmaceuticals; Prescription Drug Costs; Drug Pricing; Access To Care; Cost Reduction; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Cost Management; Germany

Find at Harvard

28 Feb 2020
News

Filling the White Space

At Able Partners, Amanda Eilian (MBA 2006) and Lisa Blau (MBA 2003) have focused primarily on women-led wellness companies, including businesses such as Goop, Moon Juice, and Daily Harvest. Now the New York–based investment firm has turned its attention to Compass... View Details

Keywords: venture capital; pharmaceutical research; innovative investing

August 2024 (Revised August 2024)
Case

Novo Nordisk Foundation

By: Debora L. Spar and Julia Comeau

In 2024, Novo Nordisk A/S was one of the most profitable firms in the world, thanks largely to just two GLP-1-based drugs, Ozempic and Wegovy. Unusually, this incredibly profitable firm was controlled not by individual private shareholders, but by a non-profit... View Details

Keywords: Pharmaceutical Companies; Diabetes; Obesity; Foundation; Non-profit Management; Profit; Corporate Governance; Business or Company Management; Corporate Social Responsibility and Impact; Expansion; Philanthropy and Charitable Giving; Nonprofit Organizations; Pharmaceutical Industry; Denmark; Europe

April 2017
Supplement

Imprimis (B)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details

Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States

November 2024
Teaching Note

Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams

By: Debora L. Spar and Julia M. Comeau

Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details

Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States; District of Columbia

January 2020
Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock

In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details

August 2018
Article

The Impact of the Entry of Biosimilars: Evidence from Europe

By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern

Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details

Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe

Find at Harvard

Register to Read

September 2014
Supplement

Pfizer and AstraZeneca: Marketing an Acquisition (B)

By: John A. Quelch and James Weber

This (B) case provides a brief description of the outcome of the (A) case. View Details

Keywords: Health Care Policy; Pharmaceutical Sales; Mergers And Acquisitions; Marketing; Pharmaceutical Industry; United Kingdom; United States

01 Mar 2007
News

Daniel Vasella

portfolio of product lines, setting Novartis apart from its global competitors. Although initially regarded by critics as too inexperienced to lead a multinational pharmaceutical company, Vasella has triumphed. Three years ago he was... View Details

Keywords: Roger Thompson; multinational pharmaceutical company; prescription drugs; vaccines; Medicare; generics business; Health, Social Assistance

April 2023 (Revised January 2024)
Background Note

Note on Healthcare in Ghana

By: Regina E. Herzlinger and Ben Creo

This note provides an overview of the healthcare system in Ghana. It discusses the public and private sector as well as traditional medical practice. It also discusses the country’s pharmaceutical industry. It is recommended as a companion to Professor Regina... View Details

Keywords: Africa; Pharmaceutical Companies; Pharmacy Benefit Manager; Health Care; Health Care Costs; Health Care Delivery; Health Care Entrepreneurship; Telehealth; Health Equity; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Business and Government Relations; Pharmaceutical Industry; Pharmaceutical Industry; Ghana

2020
Working Paper

How ESG Issues Become Financially Material to Corporations and Their Investors

By: George Serafeim

Management and disclosure of environmental, social and governance (ESG) issues have received substantial interest over the last decade. In this paper, we outline a framework of how ESG issues become financially material, affecting corporate profitability and valuation.... View Details

March 2014
Case

Novartis' Sandoz: Between Generics and Pharma

By: Krishna Palepu and Carin-Isabel Knoop

Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details

Keywords: Global Strategy And Leadership; Managing Within A Multi-Business Organization; Generic Pharmaceuticals; Global Strategy

May 2020 (Revised January 2022)
Case

Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (A)

By: Linda A. Hill, Allison J. Wigen and Emily Tedards

Michael Ku joined Pfizer in 2011, after the company had undergone three large-scale mergers and acquisitions. His mission was to drive the digital transformation of the company’s clinical supply chain, but he knew he had to start with the culture. Over the next eight... View Details

March 2016 (Revised March 2022)
Teaching Note

Express Scripts: Promoting Prescription Drug Home Delivery (A) and (B)

By: John Beshears

The pharmacy benefit manager (PBM) sector processes prescription drug claims on behalf of companies that offer a prescription drug benefit to their employees. The case associated with this teaching note follows Bob Nease, chief scientist at Express Scripts, as he... View Details

Keywords: Pharmaceuticals; Prescription Drugs; Pharmacy Benefit Manager; PBM; Healthcare; Behavioral Economics; Choice Architecture; Active Choice; Service Delivery; Decision Choices and Conditions; Consumer Behavior; Distribution Channels; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry

February 2016
Case

Express Scripts: Promoting Prescription Drug Home Delivery (A)

By: John Beshears, Patrick Rooney and Jenny Sanford

The pharmacy benefit manager (PBM) sector processes prescription drug claims on behalf of companies that offer a prescription drug benefit to their employees. This case follows Bob Nease, Chief Scientist at Express Scripts, as he considers methods to promote home... View Details

Keywords: Pharmaceuticals; Prescription Drugs; Pharmacy Benefit Manager; PBM; Healthcare; Behavioral Economics; Choice Architecture; Active Choice; Service Delivery; Decision Choices and Conditions; Health Care and Treatment; Order Taking and Fulfillment; Compensation and Benefits; Pharmaceutical Industry

Spring 2014
Article

Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company

By: Andrew Knauer and George Serafeim

Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details

Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Pharmaceutical Industry; Pharmaceutical Industry

Find at Harvard

February 2016 (Revised March 2022)
Case

Express Scripts: Promoting Prescription Drug Home Delivery (B)

By: John Beshears, Patrick Rooney and Jenny Sanford

The pharmacy benefit manager (PBM) sector processes prescription drug claims on behalf of companies that offer a prescription drug benefit to their employees. This case follows Bob Nease, Chief Scientist at Express Scripts, as he considers methods to promote home... View Details

Keywords: Pharmaceuticals; Prescription Drugs; Pharmacy Benefit Manager; PBM; Healthcare; Behavioral Economics; Choice Architecture; Active Choice; Health Care and Treatment; Service Delivery; Decision Choices and Conditions; Order Taking and Fulfillment; Compensation and Benefits

November 2013
Case

GlaxoSmithKline in China (A)

By: John A. Quelch and Margaret L. Rodriguez

Four GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to... View Details

Teaching Interest

Why is There No Cure for Health Care?

Teaching Fellow for Professor David Cutler - Harvard College Course EMREAS 20

Keywords: Health; Health Policy; Health Care; HIV; Pharmaceutical Companies; Health Care Reform; Health Economics

November 2013
Teaching Note

Cialis Lifecycle Management: Lilly's BPH Dilemma

By: Elie Ofek and Natalie Kindred

Keywords: Pharmaceuticals; Brand Management; Brand Equity; Brand Positioning; Product Management; Product Strategy; Pricing; Health Care; Health Care and Treatment; Product Marketing; Product Positioning; Brands and Branding; Marketing Strategy; Marketing; Product Launch; Pharmaceutical Industry; Pharmaceutical Industry

←
9
10
…
62
63
→